Anatomical pathology is a medical mainly concerned with diagnosing disease based on the microscopic, biochemical, macroscopic, and immunologic examination of tissues and organs. According to BlueQuark the Global Anatomic Pathology Market is expected to grow considerably during the forecasted period. Factors such as the increase in the clinical use of biomarkers enable pathologists to determine disease pathogenesis at the molecular level and further guide clinical decision-making, which is expected to drive the Anatomic Pathology Market in the forecasted period. Further, rising cases of chronic disease and increasing requirements to address the timely diagnosis of medical conditions are expected to drive the Anatomic Pathology Market in the forecasted period. Furthermore, rapid growth in the geriatric population and an increasing incidence rate of cancer and other chronic diseases are expected to drive the Anatomic Pathology Market in the forecasted period. However, the market is facing substantial problems due to a need for qualified pathologists, which results in slower response times and decreased efficiency. The need for highly skilled pathologists and the cost of anatomic pathology services could restrain the market's revenue growth.

The growing reliance on biomarkers-based pathology tests and procedures to explore common malignancy and tumorigenesis drives the market. Clinically useful biomarkers are used to develop diagnostic tests and therapeutic drugs. Pathological laboratories can rely on these biomarkers to detect and track infections and disease progression during diagnostic procedures. Hence, biomarkers are gaining ground as diagnostic and prognostic markers. They are used to extract critical information related to the pathogenesis of the disease. Therefore, pathologists can use biomarkers in their anatomic activities to form foundation data to guide them in treatment planning. For instance, in the case of colon cancer, diagnostic biomarkers used in anatomic pathology aid a better understanding of the pathways of colon carcinogenesis and help detect both sporadic and hereditary colon cancer. The role of biomarkers in pathological actions is also used for improving precision medicine using predictive biomarkers. This is further aided by advancement in whole genome sequencing, which supplements highly accurate diagnostics and treatment. Biomarkers associated with cancer detection also help determine the composition of combination drugs for each patient. Therefore, rapid advancements in anatomic pathology. Developing future biomarker assays and validation are essential to ensure accurate diagnosis, boosting the overall market growth.

The high usage of advanced pathology systems such as digital microscopes, gross imaging, and staining systems is poised to enhance anatomic pathological practices to a significant extent. Digital imaging solutions provide accuracy and specificity-related benefits over conventional techniques, thereby propelling the service uptake rate in the anatomic pathology market. Anatomy determines the cause and diagnosis of organ tissues infected by disease-causing microorganisms to understand how the syndrome affects the structure of human organs, microscopically and holistically. The approach is usually used to detect and treat various cancers and tumours. It can also help evaluate other chronic disorders such as severe infections, autoimmune diseases, liver diseases, etc. An extensive increase in the use of clinical biomarkers to determine disease pathogenesis at the molecular level enables pathologists to enhance clinical decision-making and improve patient outcomes. These factors are expected to drive the growth of the global anatomic pathology market in the forecast period.

North America is considered to have the largest revenue share owing to the presence of significant players and supportive government initiatives about training pathological programs. There is also easy accessibility to advanced technologies, government initiatives for screening cancer patients, favourable reimbursement scenarios for anatomic pathology diagnostic tests, rising healthcare expenses, and the presence of high-quality infrastructure for clinical laboratories and hospitals in the region, which are the major factors driving the growth of the Anatomic Pathology market in North America. Distinctions between diseases can be created based on variations at the molecular, tissue, fluid chemistry, cellular, and or Individual organism levels. Disease diagnosis becomes the management difference in clinical medicine, and disease administration is the foundation for everyday activities in clinics and hospitals worldwide. Morphologic diagnosis typically drives therapy. Therefore, diagnostic findings from anatomic pathologists provide the brains and order the hands of treating clinical teams.

The hospital laboratories fragment is expected to account for the highest revenue share in the forecasted period owing to the large patient poot of cancer patients, advanced infrastructure, frequent readmissions, and highly qualified staff. Hospital pathology orders are now becoming entirely digital, allowing for faster results, easier monitoring, and increased patient safety. Hospitals generate and gather data constantly, most of which is now computerized. This will enable them to use data analytics and Artificial Intelligence (Al) to gain better insights. Hospital administrators and pathologists must provide an effective and well-organized molecular pathology service that can expand to suit the continuing rise in molecular testing and personalized treatment choices. Hospitals provide tailored treatment based on the best results and evidence on time by collaborating with other stakeholders and advancing systems and networks, proving the value of healthcare services and boosting the lives of all patients. These factors are driving the growth of the Anatomic Pathology Market in the forecasted period.

The key market players are Danaher Corporation, PHC Holdings Corporation, Quest Diagnostics Incorporated, Laboratory Corporation of America Holdings, and F. Hoffmann-La Roche AG.

On 5 September 2022, Expedia, which is a global power in precision cancer diagnostics, announced that its parent company, PHC Holdings Corporation, obtained anatomical pathology providers Microm Microtech France (France) and Laurypath as part of a planned development of Epredia's European footprint.

On 13 June 2022, EmeritusDX, a fast-developing cancer diagnostics and information form, announced the acquisition of Freedom Pathology Partners to enlarge its national footprint in Anatomic Pathology, Fluorescence in-situ Hybridization, and Molecular testing.

Global Anatomic Pathology Market report provides deep insight into the Industrial market's current and future state across various regions. The study comprehensively analyses the Battery Materials market by segmenting based on Product and service (Instrument, Consumables, Antibodies, Others), Application (Disease Diagnosis, Drug Discovery and development, Others), and End-User Industry (Pathology Labs, Research Institutes, Hospitals, Others). The report examines the market drivers and restraints and the impact of COVID-19 on market growth in detail. The study covers and includes emerging market trends, developments, opportunities, and challenges in the industry. This report also covers extensively researched competitive landscape sections with prominent companies and profiles, including their market shares and projects.